Immutep Ltd (NASDAQ:IMMP)
| 2.01 Delayed Data As of May 30 |  0.00 / 0.00%Today’s Change | 1.47 Today|||52-Week Range 3.90 | +14.57% Year-to-Date |
Latest IMMP News | Press Releases
| Immutep (IMMP) Up on Initial Data From Lung Cancer Study May 25 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.01 |
| Today’s open | 2.11 |
| Day’s range | 2.01 - 2.11 |
| Volume | 12,810 |
| Average volume (3 months) | 1,128,122 |
| Market cap | $187.3M |
Data as of 3:59pm ET, 05/30/2023
Growth & Valuation
| Earnings growth (last year) | +26.62% |
| Earnings growth (this year) | -49.54% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 1,394.90 |
| Price/Book | 2.85 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CUECue Biopharma Inc | +0.07 | +1.75% |
| SELBSelecta Biosciences ... | +0.07 | +5.93% |
| CARACara Therapeutics In... | -0.09 | -2.83% |
| ADAPAdaptimmune Therapeu... | +0.07 | +6.86% |
Data as of 3:59pm ET, 06/01/2023
Financials
| Next reporting date | August 22, 2023 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $123.6K |
| Annual profit (last year) | -$23.4M |
| Net profit margin | -18,906.51% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Sydney, New South Wales (nsw) |
Forecasts
Chart unavailable
